Introduction
============

The European Renal Association -- European Dialysis and Transplant Association (ERA-EDTA) Registry's annual report describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) within Europe and adjacent countries based on data collected via the national and regional renal registries \[[@sfw135-B1]\]. On an annual basis, we publish a summary of the ERA-EDTA Registry's annual report that is intended to provide the reader with an overview of the current status of RRT for ESRD in Europe \[[@sfw135-B2]\]. In 2016, we received the 2014 data from 51 national or regional renal registries in 35 countries covering a general population of 531.7 million people. This represented 65.4% of the 2014 European general population. Thirty-two national or regional renal registries from 17 countries provided individual patient data, whereas 19 countries or regions provided aggregated data (see Appendix 1). The proportion of the European population covered by the ERA-EDTA Registry in 2014 was lower than that of 2013 (73.6%) due to the absence of Russia and Slovenia from this year's annual report.

This summary presents the 2014 incidence and prevalence of patients receiving RRT, kidney transplantation activity and the patient and graft survival in these 35 countries. The methods used to derive the results presented in this overview, along with the full results, can be found in the ERA-EDTA Registry 2014 Annual Report \[[@sfw135-B1]\].

Incidence of RRT
================

In 2014, 70 953 individuals commenced RRT for ESRD, which equated to an overall unadjusted incidence rate of 133 per million population (pmp, Table [1](#sfw135-T1){ref-type="table"}). The unadjusted incidence rate was highest in Portugal (237 pmp), Greece (218 pmp) and Cyprus (204 pmp), whereas it was lowest in the Ukraine (23 pmp) and Iceland (58 pmp, Table [1](#sfw135-T1){ref-type="table"} and Figures [1](#sfw135-F1){ref-type="fig"} and [2](#sfw135-F2){ref-type="fig"}). Of the patients commencing RRT, the majority were men (63%), over half were aged ≥65 years (55%) and a quarter had diabetes mellitus (26%) as their primary renal diagnosis (Figure [3](#sfw135-F3){ref-type="fig"}). The mean age of the patients commencing RRT in all countries and regions combined was 64.6 years (Table [1](#sfw135-T1){ref-type="table"}). However, this ranged from a mean age of 55.1 years in Albania to 70.1 years in Dutch-speaking Belgium. Of the incident patients alive and receiving RRT at day 91 after the start of treatment, the majority were receiving haemodialysis (81%), 13% were receiving peritoneal dialysis and 6% were living with a kidney transplant (Figure [4](#sfw135-F4){ref-type="fig"}). However, the modality of RRT at day 91 after the start of treatment varied considerably between age groups; as the age of the patient increased the proportion of patients receiving either peritoneal dialysis or living with a kidney transplant decreased. Furthermore, patients with a primary renal diagnosis of diabetes mellitus were half as likely to have a kidney transplant by day 91 compared with the non-diabetic group (3% versus 7%). Fig. 1Unadjusted incident rates per million population by country/region at day 1 in 2014. The incident rates for Bulgaria and the Czech Republic only include patients receiving dialysis.Fig. 2Unadjusted (left panel) and adjusted (right panel) incident rates per million population by country/region at day 1 in 2014. Registries providing individual patient data are shown as dark bars and registries providing aggregated data as light bars. The incident rate for Bulgaria and the Czech Republic only includes patients receiving dialysis.Fig. 3Unadjusted incident percentages by (**A**) gender, (**B**) age and (**C**) primary renal diagnosis at day 1 in 2014. See Appendix 1 for a list of countries and regions supplying individual patient level or aggregated level data.Fig. 4Unadjusted incident percentages of (**A**) established therapy overall, and established therapy by (**B**) gender, (**C**) age and (**D**) primary renal diagnosis at day 91 in 2014. (B)--(D) are only based on data from registries providing individual patient data. See Appendix 1 for a list of countries and regions supplying individual patient level or aggregated level data. HD, haemodialysis; PD, peritoneal dialysis; Tx, transplant; DM, diabetes mellitus.Table 1Incidence of RRT in 2014 at day 1, for all primary renal diseases combined and diabetes mellitus types 1 and 2, by count (*N*) and unadjusted rate per million population, and for all primary renal diseases combined, the mean age at the start of RRT, presented by country/regionGeneral population covered by the registry in thousandsIncidence in 2014 at day 1Total *N*Total pmpMean ageDM *N*DM pmpAlbania28632528855.13011Austria8508103612264.225930Belgium, Dutch-speaking[^a^](#tblfn3){ref-type="table-fn"}6444114517870.120732Belgium, French-speaking[^a^](#tblfn3){ref-type="table-fn"}478882817367.518839Bosnia and Herzegovina350842112060.712536Bulgaria[^b^](#tblfn4){ref-type="table-fn"}7217119716628139Croatia407064015763.718646Cyprus84717320464.65869Czech Republic[^b^](#tblfn4){ref-type="table-fn"}10 2222017197Denmark570074813164.218432Estonia13151158861.12015Finland54624618459.316530France66 26210 79116367.6237936Georgia449174316658.415935Greece10 892237221869.757553Iceland327195862.013Israel8216166820364.680798Italy (6 of 20 regions)21 274324315268.655826Latvia15901529663.32315Lithuania294330610457.84816Macedonia202226813363.26231Montenegro[^a^](#tblfn3){ref-type="table-fn"}622589356.22032Norway513752310262.49018Poland36 3384341120Portugal10 427247323779076Romania19 710299715261.144222Serbia713198513861.225035Slovakia542183115363.831658Spain46 771622913363.0152033Spain, Andalusia8394104612562.627032Spain, Aragon132916312364.14030Spain, Asturias105914713964.53331Spain, Basque country216624111165.53918Spain, Cantabria^a^5876110461.41221Spain, Castile and León[^a^](#tblfn3){ref-type="table-fn"}248729912067.67932Spain, Castile-La Mancha^a^206925212263.76230Spain, Catalonia7519117815766.025934Spain, Extremadura110012411366.02826Spain, Galicia274139814565.011442Spain, Community of Madrid645482812864.320131Spain, Region of Murcia146719413262.94631Spain, Navarre[^a^](#tblfn3){ref-type="table-fn"}6368313065.01422Spain, Valencian region500570414165.915631Sweden9696116812162.527328Switzerland[^c^](#tblfn5){ref-type="table-fn"}82308009764.515719The Netherlands16 865194111563.635821Tunisia, Sfax region118616513960.15950Turkey[^d^](#tblfn6){ref-type="table-fn"}77 69611 447147104213Ukraine42 903998231965UK, England[^a^](#tblfn3){ref-type="table-fn"}54 317631111662.3144127UK, Northern Ireland[^a^](#tblfn3){ref-type="table-fn"}18401709264.63921UK, Scotland534855710458.816431UK, Wales[^a^](#tblfn3){ref-type="table-fn"}309236411865.59430All countries531 69070 95313364.613 56632[^1][^2][^3][^4][^5][^6]

Prevalence of RRT
=================

On 31 December 2014, 490 743 individuals were receiving RRT for ESRD (Table [2](#sfw135-T2){ref-type="table"}). This equated to an unadjusted prevalence of 924 pmp. Again there was considerable variation between countries, with the highest unadjusted prevalence rates seen in Portugal (1794 pmp), the Spanish regions of Catalonia (1312 pmp), Valencia (1298 pmp), Galicia (1265 pmp) and Murcia (1258 pmp), and French- and Dutch-speaking Belgium (1250 pmp and 1238 pmp, respectively, Table [2](#sfw135-T2){ref-type="table"} and Figures [5](#sfw135-F5){ref-type="fig"} and [6](#sfw135-F6){ref-type="fig"}). The unadjusted prevalence of RRT was considerably lower in the Ukraine (157 pmp) and Albania (374 pmp). Of the prevalent patients, the majority were men (60%); however, now just under half were aged ≥65 years (44%) and a fifth had diabetes mellitus (19%) as their primary renal diagnosis (Figure [7](#sfw135-F7){ref-type="fig"}). The mean age of the prevalent patients receiving RRT in all countries and regions combined was 60.9 years (Table [2](#sfw135-T2){ref-type="table"}). This ranged from a mean age of 51.4 years in Albania to 66.4 years in Portugal. The majority of prevalent patients were receiving haemodialysis (57%), just over a third of patients were living with a kidney transplant (37%) and only 5% were receiving peritoneal dialysis (Figure [8](#sfw135-F8){ref-type="fig"}). Once again the modality of RRT varied considerably between age groups; as the age of the prevalent patients increased the proportion living with a kidney transplant decreased. For those aged 20--44 years, 65% were living with a kidney transplant, whereas this was only 40% of patients aged 65--74 years. Again prevalent patients with a primary renal diagnosis of diabetes mellitus were much less likely to be living with a kidney transplant compared with the non-diabetic group (28% versus 49%). Fig. 5Unadjusted prevalence per million population by country/region on 31 December 2014. The prevalence rates for Israel, Slovakia, Switzerland and Tunisia (Sfax region) only include patients receiving dialysis. For Romania, the overall prevalence of RRT is underestimated by 3% due to an estimated 30% underreporting of patients living on a functioning graft.Fig. 6Unadjusted (left panel) and adjusted (right panel) prevalence per million population by country/region on 31 December 2014. Registries providing individual patient data are shown as dark bars and registries providing aggregated data as light bars. The prevalence rates for Israel, Slovakia, Switzerland and Tunisia (Sfax region) only include patients receiving dialysis. For Romania, the overall prevalence of RRT is underestimated by 3% due to an estimated 30% underreporting of patients living on a functioning graft.Fig. 7Unadjusted prevalent percentages by (**A**) gender, (**B**) age and (**C**) primary renal diagnosis on 31 December 2014. See Appendix 1 for a list of countries and regions supplying individual patient level or aggregated level data.Fig. 8Unadjusted prevalent percentages of (**A**) established therapy overall, and established therapy by (**B**) gender, (**C**) age and (**D**) primary renal diagnosis on 31 December 2014. (B)--(D) are only based on data from registries providing individual patient data. See Appendix 1 for a list of countries and regions supplying individual patient level or aggregated level data. HD, haemodialysis; PD, peritoneal dialysis; Tx, transplant; DM, diabetes mellitus.Table 2Prevalence of RRT on 31 December 2014, for all primary renal diseases combined and diabetes mellitus types 1 and 2, by count (*N*) and unadjusted rate per million population, and for all primary renal diseases combined, the mean age of prevalent patients, presented by country/regionGeneral population covered by the registry in thousandsPrevalent patients on RRT in 2014Total *N*Total pmpMean ageDM *N*DM pmpAlbania2863107237451.412042Austria85089038106260.81791211Belgium, Dutch-speaking[^a^](#tblfn9){ref-type="table-fn"}64447980123865.51379214Belgium, French-speaking[^a^](#tblfn9){ref-type="table-fn"}47885983125064.61035216Bosnia and Herzegovina3508266275959.4501143Bulgaria72174168578Croatia40704295105564.61246306Cyprus847Czech Republic10 22210 9311069Denmark5700516490658.4869153Estonia131583463457.8155118Finland5462457183758.81167214France66 26280 144121062.212 604190Georgia4491209646756.143597Greece10 89213 101120363.82399220Iceland32722167556.02473Israel[^b^](#tblfn10){ref-type="table-fn"}8216628676560.92909354Italy (6 of 20 regions)21 27424 721116261.82941138Latvia159099662755.79761Lithuania29432146729Macedonia2022154376356.9225111Montenegro[^a^](#tblfn9){ref-type="table-fn"}62229647652.44776Norway5137471691859.1628122Poland36 33831 106856Portugal[^c^](#tblfn11){ref-type="table-fn"}10 42718 703179466.43332320Romania[^d^](#tblfn12){ref-type="table-fn"}19 71017 62089459.9189796Serbia7131586082258.3936131Slovakia[^b^](#tblfn10){ref-type="table-fn"}5421327360462.71067197Spain46 77155 062117759.57630163Spain, Andalusia83949537113660.01427170Spain, Aragon13291524114762.5268202Spain, Asturias10591228116062.4201190Spain, Basque country21662571118761.5264122Spain, Cantabria^a^587601102561.085145Spain, Castile and León[^a^](#tblfn9){ref-type="table-fn"}24872696108463.8467188Spain, Castile-La Mancha^a^20692180105461.6335162Spain, Catalonia75199863131262.31410188Spain, Extremadura11001221111061.4191174Spain, Galicia27413468126561.9600219Spain, Community of Madrid64546739104461.41183183Spain, Region of Murcia14671845125861.7251171Spain, Navarre[^a^](#tblfn9){ref-type="table-fn"}636714112261.979124Spain, Valencian region50056495129862.7853170Sweden9696926395559.51641169Switzerland[^b^](#tblfn10){ref-type="table-fn"}8230283434468.154066The Netherlands16 86516 31196759.91991118Tunisia, Sfax region[^b^](#tblfn10){ref-type="table-fn"}118680667858.2140118Turkey[^e^](#tblfn13){ref-type="table-fn"}77 69671 318918282136Ukraine42 903674215790221UK, England[^a^](#tblfn9){ref-type="table-fn"}54 31749 69891558.48043148UK, Northern Ireland[^a^](#tblfn9){ref-type="table-fn"}1840159886858.2243132UK, Scotland5348475789056.5724135UK, Wales[^a^](#tblfn9){ref-type="table-fn"}3092282891559.5483156All countries531 690490 74392460.962 962155[^7][^8][^9][^10][^11][^12][^13]

Kidney transplantation
======================

In 2014, 19 406 kidney transplantations were performed that equated to an overall unadjusted transplant rate of 36 pmp (Figure [9](#sfw135-F9){ref-type="fig"}). Again this figure varied considerably between countries with the highest unadjusted transplant rates seen in the Netherlands (59 pmp), Spain (57 pmp) and Norway (53 pmp), with some Spanish regions reaching even higher rates. Conversely, the lowest unadjusted transplant rates were reported in the Ukraine (2 pmp), Georgia (6 pmp) and Bulgaria (7 pmp). Overall the unadjusted deceased donor transplant rate was more than double that of the unadjusted living donor transplant rate (27 pmp versus 12 pmp, Figure [10](#sfw135-F10){ref-type="fig"}; 68% versus 31%, Figure [11](#sfw135-F11){ref-type="fig"}). The highest unadjusted rates of deceased donor transplants were seen in Spain (48 pmp), Croatia (46 pmp) and the Czech Republic (43 pmp, Figure [10](#sfw135-F10){ref-type="fig"}), whereas the highest unadjusted rate of living donor transplants were seen in the Netherlands (31 pmp), Turkey (30 pmp) and Northern Ireland (28 pmp, Figure [10](#sfw135-F10){ref-type="fig"}). Fig. 9Kidney transplants performed in 2014, as counts and per million population (unadjusted) by country/region. Registries providing individual patient data are shown as dark bars and registries providing aggregated data as light bars. Data based on patients aged ≥20 years in Dutch-speaking Belgium, French-speaking Belgium, Montenegro, the Spanish regions of Cantabria, Castile and León, Castile-La Mancha and Navarre, and the UK: England, Northern Ireland and Wales. The total count for Austria is based on residents and non-residents. For Romania the transplantation activity reflects 70% of the total transplantation activity in the country due to an underreporting of pre-emptive transplantation.Fig. 10Unadjusted deceased donor (left panel) and living donor (right panel) kidney transplants per million population performed in 2014 by country/region. Registries providing individual patient data are shown as dark bars and registries providing aggregated data as light bars. Data based on patients aged ≥20 years in Dutch-speaking Belgium, French-speaking Belgium, Montenegro, the Spanish regions of Cantabria, Castile and León, Castile-La Mancha and Navarre, and the UK: England, Northern Ireland and Wales. The total count for Austria is based on residents and non-residents. For Romania, the transplantation activity reflects 70% of the total transplantation activity in the country due to an underreporting of pre-emptive transplantation.Fig. 11Percentage of kidney transplants performed in 2014 by kidney donor type. See Appendix 1 for a list of countries and regions supplying individual patient level or aggregated level data.

Survival of patients receiving RRT
==================================

For patients commencing RRT in the period 2005--09, the 1-, 2- and 5-year-adjusted patient survival probabilities on all RRT modalities were 90.0% \[95% confidence interval (CI) 89.9--90.2\], 82.8% (95% CI 82.6--83.0) and 63.3% (95% CI 63.0--63.6), respectively (see Appendix 2 and Table [3](#sfw135-T3){ref-type="table"} for a description of the adjustments made and the countries/regions included in this analysis). For the same cohort of patients commencing dialysis between 2005 and 2009, the 1-, 2- and 5-year-adjusted patient survival probabilities (with kidney transplantation considered as a censored event) were 88.1% (95% CI 87.9--88.2), 79.5% (95% CI 79.2--79.7) and 55.7% (95% CI 55.3--56.1), respectively. Patient survival after a first kidney transplant performed during 2005 and 2009 was much better than for those patients receiving dialysis (Figure [12](#sfw135-F12){ref-type="fig"}). For those with a transplant, 5-year-adjusted patient and graft survival remain higher with a living donor transplant compared with a deceased donor transplant \[95.7% (95% CI 95.2--96.2) versus 92.3% (95% CI 91.9--92.7) for patient survival and 87.0% (95% CI 86.3--87.8) versus 81.6% (95% CI 81.1--82.2) for graft survival. See Appendix 2 and Table [3](#sfw135-T3){ref-type="table"} for a description of the adjustments made and the countries/regions included in this analysis.\]. Fig. 12The 5-year adjusted survival probability of incident dialysis patients (commencing RRT between 2005 and 2009) and patients receiving a first transplant (between 2005 and 2009) from day 91 by modality, adjusted for age, gender and primary renal diagnosis. Survival on dialysis was examined using the Cox regression method, with transplantation as a censored event (see the ERA-EDTA 2014 Annual Report for the full methods). Analyses were adjusted using fixed values: age (60 years), gender (60% men) and primary renal diagnosis (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other causes). This figure is based on data from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Valencian region), Sweden, the Netherlands and the UK (all countries).Table 3The 1-, 2- and 5-year survival probabilities by treatment modality and cohort from day 1 of the start of RRT/dialysis or from the day of transplantationSurvival probabilities as percentage (95% CI)Cohort: 2005--09Cohort: 2008--121 year2 year5 year1 year2 yearPatient survival on RRT Unadjusted82.7 (82.5--82.8)72.0 (71.8--72.1)49.4 (49.2--49.5)83.8 (83.6--84.0)73.7 (73.5--73.9) Adjusted[^a^](#tblfn15){ref-type="table-fn"}90.0 (89.9--90.2)82.8 (82.6--83.0)63.3 (63.0--63.6)90.6 (90.4--90.7)83.8 (83.6--84.0)Patient survival on dialysis (with kidney transplantation as a censored observation) Unadjusted81.7 (81.5--81.9)69.7 (69.5--69.9)41.5 (41.3--41.6)82.7 (82.6--82.9)71.3 (71.1--71.4) Adjusted[^a^](#tblfn15){ref-type="table-fn"}88.1 (87.9--88.2)79.5 (79.2--79.7)55.7 (55.3--56.1)89.0 (88.9--89.2)81.1 (80.8--81.3)Patient survival after first kidney transplantation (deceased donor) Unadjusted96.1 (95.8--96.3)94.2 (93.9--94.5)87.9 (87.5--88.3)96.4 (96.1--96.6)94.4 (94.1--94.6) Adjusted[^b^](#tblfn16){ref-type="table-fn"}97.6 (97.4--97.8)96.4 (96.2--96.6)92.3 (91.9--92.7)98.0 (97.8--98.1)96.8 (96.6--97.0)Graft survival after first kidney transplantation (deceased donor) Unadjusted90.9 (90.6--91.2)88.1 (87.7--88.4)79.0 (78.6--79.4)91.2 (90.9--91.5)88.3 (88.0--88.6) Adjusted[^b^](#tblfn16){ref-type="table-fn"}92.2 (91.8--92.5)89.7 (89.3--90.1)81.6 (81.1--82.2)92.7 (92.4--93.0)90.2 (89.8--90.6)Patient survival after first kidney transplantation (living donor) Unadjusted98.4 (98.1--98.7)97.5 (97.1--97.8)94.2 (93.7--94.7)98.8 (98.6--99.0)97.9 (97.6--98.2) Adjusted[^b^](#tblfn16){ref-type="table-fn"}98.8 (98.6--99.1)98.2 (97.9--98.5)95.7 (95.2--96.2)99.2 (99.0--99.3)98.6 (98.3--98.8)Graft survival after first kidney transplantation (living donor) Unadjusted95.5 (95.0--95.9)93.6 (93.0--94.1)87.0 (86.4--87.7)96.3 (95.9--96.6)94.5 (94.1--94.9) Adjusted[^b^](#tblfn16){ref-type="table-fn"}95.5 (95.0--96.0)93.7 (93.1--94.2)87.0 (86.3--87.8)96.3 (96.0--96.7)94.6 (94.2--95.1)[^14][^15][^16]

Expected remaining lifetime
===========================

There remains a substantial difference in the expected remaining lifetime between the general population and those receiving dialysis (Figure [13](#sfw135-F13){ref-type="fig"}). Patients aged 20--45 years old receiving dialysis are expected to live only one-third as long as the age-matched general population. The prospect is even worse for patients aged 55--64 years, as they are expected to live only a quarter as long as their age-matched counterparts in the general population. Patients living with a kidney transplant fare better than their counterparts receiving dialysis. However, for the transplant recipients aged 20--49 years their life expectancy is still approximately one-third less than that of the age-matched general population. As the age of the transplant recipient increases, the disparity in life expectancy with the age-matched general population also increases. Fig. 13Expected remaining lifetimes of the general population in 2013 and 2014, and of prevalent dialysis and transplant patients in 2013 and 2014 (includes mortality in the first 90 days), by age and gender. This figure is based on data from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Bosnia and Herzegovina, Denmark, Estonia, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castille and León), Spain (Castille-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Community of Madrid), Spain (Region of Murcia), Spain (Valencian region), Sweden, the Netherlands and the UK (all countries).

Affiliated registries
=====================

Albanian Renal Registry (M. Barbullushi, A. Koroshi and all team of Nephrology); Austrian Dialysis and Transplant Registry (OEDTR) (R.K.); Dutch-speaking Belgian Society of Nephrology (NBVN) (B. De Moor, F. Schroven and J. De Meester); French-speaking Belgian Society of Nephrology (GNFB) (J.M.d.G. and F. Collart); Renal Registry Bosnia and Herzegovina (H.R., L. Lukić and S. Corić); Bulgaria (E.S.V., I. Velinova and M. Gitcheva); Croatian Registry of Renal Replacement Therapy (CRRRT) (I.B., S. Rački and N. Janković); Cyprus Renal Registry (K.I. and all of the renal units providing data); Czech Republic: Registry of Dialysis Patients (RDP) (I. Rychlík, J. Potucek and F.L.); Danish Nephrology Registry (DNS) (J.G.H.); Estonian Society of Nephrology (Ü. Pechter, M.R. and K. Lilienthal); Finnish Registry for Kidney Diseases (P.F. and C. Grönhagen-Riska); France: The Epidemiology and Information Network in Nephrology (REIN) (M.L. and C. Couchoud); Georgian Renal Registry (N.K. and Dialysis Nephrology and Transplantation Union of Georgia); Hellenic Renal Registry (N.A.); Icelandic End-Stage Renal Disease Registry (R.P.); Israel National Registry of Renal Replacement Therapy (R. Dichtiar, T. Shohat and E.G.); Italian Registry of Dialysis and Transplantation (RIDT) (M.N., M. Postorino and A. Limido); Latvian Renal Registry (H.C. and V. Kuzema); Lithuanian Renal Registry (V. Kuzminskis, I.A. Bumblytė and E.Ž.); Macedonian Renal Registry (L. Trpenovski, Z. Seljami and O.S.-T.); Montenegrin Renal Registry (M.R., D. Radunovic and V. Prelevic); Norwegian Renal Registry (T. Leivestad, A.V. Reisæter and A.Å.); Polish Renal Registry (B.R., M. Klinger and G. Korejwo); Portuguese Renal Registry (F.M., F. Nolasco and R. Filipe); Romanian Renal Registry (RRR) (G. Mircescu, L.G. and E. Podgoreanu); Renal Registry in Serbia (Working Group of Serbian RRT Registry and all of the Serbian renal units); Slovakian Renal Registry (V.S., I. Lajdová and M. Karolyova); Spanish RRT National Registry at ONT, Spanish Regional Registries and Spanish Society of Nephrology (SEN) and the regional registries of Andalusia (SICATA) (P.C.d.l.N.), Aragon (J.I. Sanchez Miret and J.M. Abad Diez), Asturias (R. A.d.l.T., J.R. Quirós and RERCA Working Group), Basque country (UNIPAR) (Á.M., J. Aranzabal, M. Rodrigo and I. Moina), Cantabria (M. Arias Rodríguez and O. García Ruiz), Castile and León (R.G. and C. Fernández-Renedo), Castile-La Mancha (G. Gutiérrez Ávila and I.M.A.), Catalonia (RMRC) (E. Arcos, J. Comas and J. Tort), Extremadura (J.M. Ramos Aceitero and M.A.G.B.), Galicia (E.B.C. and J. Sánchez-Ibáñez), Community of Madrid (M.I.A.M.), Renal Registry of the Region of Murcia (C.S.d.P. and I. Marín Sánchez), Navarre (M.F.S.R., J. Manrique Escola and J. Arteaga Coloma) and the Valencian region (REMRENAL) (C. Alberich Martí and M.F.A.); Swedish Renal Registry (SNR) (K.G. Prütz, M.E.S., M. Evans, S. Schön, L. Bäckman and M. Segelmark); Swiss Dialysis Registry (P. Ambühl and R. Winzeler); Dutch Renal Registry (RENINE) (M.H.H. and A. Hemke); Tunisia, Sfax region (D. Zalila, S. Toumi and F.J.); Registry of the Nephrology, Dialysis and Transplantation in Turkey (TSNNR) (G. Süleymanlar, N.S. and K. Ateş); Ukrainian Renal Data System (URDS) (M.K., S. Nikolaenko and O. Dubyna); UK Renal Registry (UKRR) (all the staff of the UK Renal Registry and of the renal units submitting data); Scottish Renal Registry (SRR) (all of the Scottish renal units).
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*Countries or regions providing individual patient level data.* Austria, Dutch-speaking Belgium, French-speaking Belgium, Bosnia and Herzegovina, Denmark, Estonia, Finland, France, Greece, Iceland, Montenegro, Norway, Romania, Serbia, the Spanish regions of Andalusia, Aragon, Asturias, Basque country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura, Galicia, Community of Madrid, Murcia, Navarre and Valencian region, Sweden, the Netherlands, UK (England/Northern Ireland/Wales) and UK (Scotland).

*Countries or regions providing aggregated patient level data.* Albania, Bulgaria, Croatia, Cyprus, Czech Republic, Georgia, Israel, Italy, Latvia, Lithuania, Macedonia, Poland, Portugal, Slovakia, Spain, Switzerland, Tunisia (Sfax region), Turkey and Ukraine.

Analyses for patient survival on RRT and dialysis were adjusted using the following fixed values: age (60 years), gender (60% men) and primary renal diagnosis (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other causes).

Analyses for patient and graft survival after a first kidney transplant were adjusted using the following fixed values: age (45 years), gender (60% men) and primary renal diagnosis (10% diabetes mellitus, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other causes).

The survival analyses presented here were based on data from Austria, Dutch- and French-speaking Belgium, Denmark, Finland, France, Greece, Iceland, Norway, the Spanish regions of Andalusia, Aragon, Asturias, Basque country, Cantabria, Castile and León, Castile-La Mancha, Catalonia, Extremadura, Galicia and Valencian region, Sweden, the Netherlands and the UK.

[^1]: When cells are left empty, the data are unavailable and, therefore, could not be used for the calculation of the summary data.

[^2]: DM, diabetes mellitus as cause of renal failure.

[^3]: Patients younger than 20 years of age are not reported. The true incidence counts are, therefore, slightly higher than the counts reported here.

[^4]: Data on incidence include dialysis patients only.

[^5]: Data on incidence of cause of renal failure (DM) include dialysis patients only.

[^6]: Data on incidence of cause of renal failure (DM) are based on 2836 of 11 447 patients (24.8%).

[^7]: When cells are left empty, the data are unavailable and, therefore, could not be used for the calculation of the summary data.

[^8]: DM, diabetes mellitus as cause of renal failure.

[^9]: Patients younger than 20 years of age are not reported. The true prevalent counts are, therefore, slightly higher than the counts reported here.

[^10]: Data on prevalence include dialysis patients only.

[^11]: Data on prevalence of cause of renal failure (DM) include dialysis patients only.

[^12]: The overall prevalence of RRT is underestimated by approximately 3% due to an estimated 30% underreporting of patients living on a functioning graft.

[^13]: Data on the prevalence of cause of renal failure (DM) are based on 8897 of 71 318 patients (12.5%).

[^14]: This is based on data from the following registries providing individual patient data: Austria, Belgium (Dutch-speaking), Belgium (French-speaking), Denmark, Finland, France, Greece, Iceland, Norway, Spain (Andalusia), Spain (Aragon), Spain (Asturias), Spain (Basque country), Spain (Cantabria), Spain (Castile and León), Spain (Castile-La Mancha), Spain (Catalonia), Spain (Extremadura), Spain (Galicia), Spain (Valencian region), Sweden, the Netherlands and the UK (all countries).

[^15]: Analyses were adjusted using fixed values: age (60 years), gender (60% men) and primary renal disease (20% diabetes mellitus, 17% hypertension/renal vascular disease, 15% glomerulonephritis and 48% other causes).

[^16]: Analyses were adjusted using fixed values: age (45 years), gender (60% men) and primary renal disease (10% diabetes mellitus, 8% hypertension/renal vascular disease, 28% glomerulonephritis and 54% other causes).
